Unknown

Dataset Information

Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells.


ABSTRACT: Preclinical studies using bone marrow derived cells to treat traumatic brain injury have demonstrated efficacy in terms of blood-brain barrier preservation, neurogenesis, and functional outcomes. Phase 1 clinical trials using bone marrow mononuclear cells infused intravenously in children with severe traumatic brain injury demonstrated safety and potentially a central nervous system structural preservation treatment effect. This study sought to confirm the safety, logistic feasibility, and potential treatment effect size of structural preservation/inflammatory biomarker mitigation in adults to guide Phase 2 clinical trial design. Adults with severe traumatic brain injury (Glasgow Coma Scale 5-8) and without signs of irreversible brain injury were evaluated for entry into the trial. A dose

SUBMITTER: Cox CS 

PROVIDER: S-EPMC5367945 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature